Weight management · Phase 3
GLORY-1: weight management in China
What was tested?
Mazdutide versus placebo in Chinese adults with overweight or obesity. ↗
Registered primary question: Percentage weight change and the proportion losing at least 5% of baseline weight at week 32. ↗
What the reviewed report found
Journal year 2025 · Article summary reviewed 2026-09-15
At week 32, intention-to-treat weight changes were −10.09% and −12.55% in active groups versus +0.45% with placebo. Gastrointestinal adverse events were common; adverse-event discontinuation occurred in 1.5%, 0.5% and 1.0%, respectively.↗
Keep in context: The study continued to week 48, but the coprimary endpoints were assessed at week 32. Its population and analysis definition should accompany any quoted weight result. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 610 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Triple
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2024-11-12; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
GLORY-1: obesity in China
- Design in the report
- Randomized, double-blind, placebo-controlled phase 3 trial; NCT05607680.↗
- Participants in the report
- 610 adults with overweight or obesity participated.↗
- Limitations
- The study concerns its enrolled population and prespecified follow-up. Weight change alone cannot establish cardiovascular benefit or longer-term safety.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study of IBI362 in Participants With Obesity or Overweight ↗
Protocol identifier: CIBI362B301. Sponsor: Innovent Biologics (Suzhou) Co. Ltd..
Retrieved 2026-09-20; SHA-256 33c70991be03030b423c07b0b935275dc3dad26bb90fedb0b072cc5b24b27531.
PMID 40421736
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 40421736. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 3f1a92c9c5640d494093aeaff53a8a7f33e7f6147c381db152785819de20e041.